Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
105.00    1.80 (1.74%)
Bid:
104.00
Ask:
105.00
Spread: 1.00 (0.962%)
Market Cap: £172.14m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading and refinancing update

19 Mar 2026 07:00

RNS Number : 2207X
Synthomer PLC
19 March 2026
 

Synthomer plcTrading and refinancing update

 

· 2025 performance reconfirmed with positive cash, robust earnings and improved margin performance

· 2026 started as expected; in line with prior year and with momentum building

· Focused on refinancing discussions and divestment programme, which are both progressing constructively

 

2025 results and current trading in 2026

 

Synthomer plc ("Synthomer" or the "Company") today announces that the year to 31 December 2025 audit process is well-advanced, with no change to the expectations indicated in the 29 January 2026 trading update of continuing revenue of c.£1.74bn and continuing EBITDA in the range of £135-138m.

 

Strong operational execution, together with expanded 'self-help' cost reduction programmes, enabled the Company to mitigate the impact of softer end-market demand since global tariff changes were announced and deliver resilient earnings and an increased EBITDA margin as well as positive Free Cash Flow in 2025.

 

Synthomer's covenant net debt:EBITDA was 4.7-4.8x as at 31 December 2025, well within the requirement of less than 5.25x, and the Company's liquidity (undrawn committed facilities and cash) was £385m.

 

Overall trading since the start of 2026 is in line with the Company's expectations and momentum continues to build. While the consequences of the military action in Iran remain uncertain, Synthomer is passing through the significant increases in underlying raw materials and energy costs since the start of the conflict via pricing adjustments, while sales volumes in several product areas are increasing, benefitting from our regional manufacturing footprint. The Company's joint venture manufacturing operation and sales office in the Middle East are both currently operating as usual, and our global supply chains have remained robust to-date although we are monitoring the situation closely.

 

The Company continues to focus on delivering further year-on-year progress in 2026 driven primarily by its self-help actions.

 

Update on refinancing discussions

 

As previously announced, the Company remains actively engaged with its lenders with the objective of amending the key covenants and extending the maturity of its revolving credit and UK Export Finance debt facilities, which are due in H2 2027. These discussions are proceeding constructively, alongside our ongoing focus on delivering the broadened divestment programme. While the Company continues to explore options to support further leverage reduction and underpin the sustained delivery of the speciality chemicals strategy, the Board does not currently intend to issue new equity and is focused on concluding the debt refinancing process alongside the divestment programme. Kuala Lumpur Kepong Berhad Group ('KLK'), Synthomer's largest shareholder, remains very supportive of Synthomer's strategy and operational delivery.

 

Given the debt refinancing process above, the Company will publish its 2025 results in late April 2026.

 

 

Further information:

Investors: Faisal Tabbah, Vice President Investor Relations

Tel: +44 (0) 1279 775 306

Media: Nick Hasell, FTI Consulting

Tel: +44 (0) 203 727 1340

 

Notes

Synthomer plc is a leading supplier of high-performance, highly specialised polymers and ingredients that play vital roles in key sectors such as coatings, construction, adhesives, and health and protection - growing markets for customers who serve billions of end users worldwide. Headquartered in London, UK and listed there since 1971, we employ c.3,800 employees across our five innovation centres of excellence and 29 manufacturing sites across Europe, North America, Middle East and Asia. With more than 6,000 blue-chip customers and £1.7bn in continuing revenue in 2025, our business is built around three divisions, serving customers in attractive end markets where demand is driven by global megatrends including urbanisation, demographic change, climate change and sustainability, and shifting economic power. In Coatings & Construction Solutions, our specialist polymers enhance the sustainability and performance of a wide range of coatings and construction products. We serve customers in applications including architectural and masonry coatings, mortar modification, waterproofing and flooring, fibre bonding, and energy solutions. In Adhesive Solutions our products help our customers bond, modify and compatibilise surfaces and components for applications including tapes and labels, packaging, hygiene, tyres and plastic modification, improving permeability, strength, elasticity, damping, dispersion and grip. In Health & Protection and Performance Materials we are a world-leading supplier of water-based polymers for medical gloves, and a major European manufacturer of high-performance binders, foams and other products serving customers in a range of end markets. Our purpose is creating innovative and sustainable solutions for the benefit of customers and society. Around 20% of our sales volumes are from new and patent protected products. At our innovation centres of excellence in the UK, China, Germany, Malaysia and Ohio, USA we collaborate closely with our customers to develop new products and enhance existing ones tailored to their needs, with an increasing range of sustainability benefits. Our 2030 decarbonisation targets have been approved by the Science Based Targets initiative as being in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement, and since 2021 we have held the London Stock Exchange Green Economy Mark, which recognises green technology businesses making a significant contribution to a more sustainable, low-carbon economy. Find us at www.synthomer.com or search for Synthomer on LinkedIn. Legal Entity Identifier (LEI): 213800EHT3TI1KPQQJ56.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFSESAEMSEFD
Date   Source Headline
6th Nov 20084:37 pmRNSPrice Monitoring Extension
21st Oct 20086:24 pmRNSHolding(s) in Company
21st Oct 20086:24 pmRNSHolding(s) in Company
8th Sep 20084:41 pmRNSSecond Price Monitoring Extn
8th Sep 20084:36 pmRNSPrice Monitoring Extension
2nd Sep 200812:26 pmRNSHolding(s) in Company
27th Aug 20087:00 amRNSInterim Results
14th Aug 20088:59 amRNSNotice of Results
12th Aug 20087:00 amRNSSale Completion
5th Aug 20089:42 amRNSBlocklisting Interim Review
1st Aug 200812:03 pmRNSHolding(s) in Company
21st Jul 20087:00 amRNSDisposal
27th Jun 20087:00 amRNSSale Completion
26th Jun 200810:17 amRNSHolding(s) in Company
18th Jun 200811:44 amRNSHolding(s) in Company
17th Jun 200810:12 amRNSDirector/PDMR Shareholding
16th Jun 20085:14 pmRNSDirector/PDMR Shareholding
16th Jun 200810:33 amRNSDirector/PDMR Shareholding
2nd Jun 20082:57 pmRNSBlocklisting Interim Review
30th May 20082:37 pmRNSSale Completion
15th May 20084:17 pmRNSResult of AGM
15th May 20087:00 amRNSTrading Update
9th May 20081:44 pmRNSHolding(s) in Company
24th Apr 20083:00 pmRNSAnnual Information Update
14th Apr 20084:43 pmRNSAnnual Report and Accounts
8th Apr 20089:55 amRNSDirector/PDMR Shareholding
7th Apr 20084:30 pmRNSHolding(s) in Company
14th Mar 200811:48 amRNSDirector/PDMR Shareholding
14th Mar 200811:46 amRNSDirector/PDMR Shareholding
12th Mar 20087:00 amRNSFinal Results
11th Feb 20082:40 pmRNSBlocklisting Interim Review
11th Feb 20087:01 amRNSDisposal
14th Dec 20077:00 amRNSPre-close Trading Statement
30th Nov 20073:37 pmRNSBlocklisting Interim Review
28th Nov 20072:46 pmRNSHolding(s) in Company
22nd Nov 20074:25 pmRNSDirector/PDMR Shareholding
24th Sep 200710:00 amRNSGroup Finance Director
6th Sep 20077:01 amRNSInterim Results
21st Aug 20077:00 amRNSBoard Appointments
14th Aug 20079:30 amRNSHolding(s) in Company
8th Aug 200712:16 pmRNSHolding(s) in Company
1st Aug 20077:01 amRNSPlant reorganisation
24th Jul 20072:05 pmRNSHolding(s) in Company
20th Jul 20073:50 pmRNSHolding(s) in Company
13th Jul 200712:47 pmRNSHolding(s) in Company
22nd Jun 200711:16 amRNSHolding(s) in Company
1st Jun 200711:25 amRNSBlocklisting Interim Review
1st Jun 20077:01 amRNSDivisional restructuring
29th May 20072:44 pmRNSHolding(s) in Company
17th May 20074:41 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.